These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35113275)

  • 1. Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases.
    Kochar BD; Cheng D; Cai T; Ananthakrishnan AN
    Dig Dis Sci; 2022 Nov; 67(11):5206-5212. PubMed ID: 35113275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases.
    Cheng D; Kochar BD; Cai T; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2366-2372.e6. PubMed ID: 35066137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
    Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
    CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study.
    McCurdy JD; Kuenzig ME; Smith G; Spruin S; Murthy SK; Carrier M; Nguyen GC; Benchimol EI
    Inflamm Bowel Dis; 2020 Oct; 26(11):1761-1768. PubMed ID: 31995204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
    Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
    Desai RJ; Pawar A; Khosrow-Khavar F; Weinblatt ME; Kim SC
    Rheumatology (Oxford); 2021 Dec; 61(1):121-130. PubMed ID: 33752237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
    Misra DP; Pande G; Agarwal V
    Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis.
    Zhang XY; Dong HC; Wang WF; Zhang Y
    World J Gastroenterol; 2022 Apr; 28(16):1705-1717. PubMed ID: 35581968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study.
    Kuenzig ME; Bitton A; Carroll MW; Kaplan GG; Otley AR; Singh H; Nguyen GC; Griffiths AM; Stukel TA; Targownik LE; Jones JL; Murthy SK; McCurdy JD; Bernstein CN; Lix LM; Peña-Sánchez JN; Mack DR; Jacobson K; El-Matary W; Dummer TJB; Fung SG; Spruin S; Nugent Z; Tanyingoh D; Cui Y; Filliter C; Coward S; Siddiq S; Benchimol EI
    J Crohns Colitis; 2021 Dec; 15(12):2031-2040. PubMed ID: 34175936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease.
    Fujiya M; Kawaguchi T; Arai S; Isogawa N; Hiro S; Matsumoto F; Yamaguchi S; Yoshii N; Nakamura M; Matsuoka K
    Dig Dis Sci; 2022 Nov; 67(11):5195-5205. PubMed ID: 35150345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of arterial thrombotic events in inflammatory bowel disease.
    Ha C; Magowan S; Accortt NA; Chen J; Stone CD
    Am J Gastroenterol; 2009 Jun; 104(6):1445-51. PubMed ID: 19491858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.